Q9NTG7 (SIR3_HUMAN) Homo sapiens (Human)
NAD-dependent protein deacetylase sirtuin-3, mitochondrial UniProtKBInterProSTRINGInteractive Modelling
399 aa; Sequence (Fasta) ; (Isoform 2)
Available Structures
40 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Ligands | ||
|---|---|---|---|---|---|---|
| Crystal structure of SIRT3 in complex with H4K16la peptide |
Heteromer P62805; | 1×ZN; 1×2OP; | ||||
| Assess | ||||||
| Crystal structure of human Sirt3 in complex with an acetylated HIV1 Tat-46-54 substrate peptide |
Heteromer P12506; | 1×ZN; | ||||
| Assess | ||||||
| Crystal Structure of human SIRT3 with acetyl-lysine AceCS2 peptide |
Heteromer Q9NUB1; | 2×ZN; 4×SO4; 2×BCT; 2×GOL; | ||||
| Assess | ||||||
| Crystal Structure of SIRT3 with a H3K9 Peptide Containing a Myristoyl Lysine |
Heteromer Q6NXT2; | 1×ZN; | ||||
| Assess | ||||||
| Crystal Structure of SIRT3 in complex with H3K9bhb peptide |
Heteromer V9H1G0; | 1×ZN; | ||||
| Assess | ||||||
| Crystal structure of human Sirt3 in complex with an inhibiting HIV1 Tat-37-59 peptide |
Heteromer P12506; | 1×ZN; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF HUMAN SIRT3 IN COMPLEX WITH THIOALKYLIMIDATE FORMED FROM THIO-ACETYL-LYSINE AC… |
Heteromer Q9NUB1; | 1×ZN; 1×CL; 1×PEG; 1×SO4; 1×EDO; | ||||
| Assess | ||||||
| Crystal Structure of Human SIRT3 with ADPR bound to the AceCS2 peptide containing a thioacetyl lysi… |
Heteromer Q9NUB1; | 1×ZN; 1×SO4; 1×CO3; | ||||
| Assess | ||||||
| Crystal Structure of Human SIRT3 in Complex with a Palmitoyl H3K9 Peptide |
Heteromer Q6NXT2; | 1×PLM; 1×ZN; | ||||
| Assess | ||||||
| Crystal Structure of Human SIRT3 with AceCS2 peptide |
Heteromer Q9NUB1; | 4×SO4; 2×ZN; | ||||
| Assess | ||||||
| Crystal structure of SIRT3 bound to a leucylated AceCS2 |
Heteromer Q9NUB1; | 6×ZN; 6×LEU; 2×LYS; | ||||
| Assess | ||||||
| Crystal structure of human Sirt3 in complex with a fragment of the human AROS protein |
Heteromer Q86WX3; | 1×ZN; | ||||
| Assess | ||||||
| Human SIRT3 Recognizing CCNE2K348la peptide |
Heteromer O96020; | 2×ZN; 2×IMD; | ||||
| Assess | ||||||
| Crystal Structure of SIRT3 in complex with H3K4bhb peptide |
Heteromer V9H1G0; | 1×ZN; 2×GOL; 1×SO4; 1×CIT; | ||||
| Assess | ||||||
| Complex of human Sirt3 with Bromo-Resveratrol and ACS2 peptide |
Heteromer Q9NUB1; | 1×BVB; 1×ZN; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF HUMAN SIRT3 IN COMPLEX WITH NATIVE ALKYLIMIDATE FORMED FROM ACETYL-LYSINE ACS2… |
Heteromer Q9NUB1; | 7×EDO; 3×GOL; 2×SO4; 1×PEG; 1×ZN; 1×XYQ; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF HUMAN SIRT3 IN COMPLEX WITH THIOALKYLIMIDATE FORMED FROM THIO-ACETYL-LYSINE AC… |
Heteromer Q9NUB1; | 1×ZN; 1×EDO; | ||||
| Assess | ||||||
| Crystal Structure of SIRT3 in complex with H4K16bhb peptide |
Heteromer P62805; | 1×ZN; | ||||
| Assess | ||||||
| Crystal structure of SIRT3 in complex with H3K23la peptide |
Heteromer P68431; | 3×GOL; 1×EDO; 1×ZN; 1×2OP; | ||||
| Assess | ||||||
| Crystal structure of SIRT3 in complex with acetyl p53 peptide coupled with 4-amino-7-methylcoumarin |
Heteromer P04637; | 1×ZN; | ||||
| Assess | ||||||
| Human SIRT3 in complex with halistanol sulfate |
Heteromer Q9NUB1; | 1×ZN; 1×8QF; | ||||
| Assess | ||||||
| 14-3-3 sigma sirtuin-3 phospho-peptide complex |
Heteromer P31947; | 6×MG; 4×CA; 2×CL; | ||||
| Assess | ||||||
| Crystal Structure of human SIRT3 with ELT inhibitor 11c [N-{2-[1-(6-carbamoylthieno[3,2-d]pyrimidin… | monomer | 1×ZN; 1×1NQ; | ||||
| Assess | ||||||
| Crystal Structure of human SIRT3 with ELT inhibitor 3 [14-(4-{2-[(methylsulfonyl)amino]ethyl}piperi… | monomer | 1×ZN; 1×1NS; 2×GOL; 1×NA; | ||||
| Assess | ||||||
| Crystal Structure of human SIRT3 with ELT inhibitor 28 [4-(4-{2-[(2,2-dimethylpropanoyl)amino]ethyl… | monomer | 1×ZN; 1×1NR; | ||||
| Assess | ||||||
| Human SIRT3 bound to Ac-ACS peptide and Carba-NAD | monomer | 1×CNA; 3×SO4; 1×ZN; 1×GOL; | ||||
| Assess | ||||||
| Human SIRT3 Recognizing H3K4cr | monomer | 1×ZN; 1×CRD; | ||||
| Assess | ||||||
| Human SIRT3 co-crystallized with ligands, including p53-AMC peptide and Carba-NAD | monomer | 1×CNA; 1×ZN; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF HUMAN SIRT3 IN COMPLEX WITH THE INHIBITOR EX-527 AND ADP-RIBOSE | monomer | 1×OCZ; 1×AR6; 1×ZN; | ||||
| Assess | ||||||
| Crystal structure of human SIRT3 in complex with compound (2-butylbenzofuran-3-yl)(4-(2-(diethylami… | monomer | 1×ZN; 1×BBI; | ||||
| Assess | ||||||
| Human SIRT3 bound to p53-AMC peptide, Carba-NAD, and Honokiol | monomer | 1×ZN; 1×CNA; | ||||
| Assess | ||||||
| Crystal Structure of Human SIRT3 | monomer | 1×ZN; 1×PGE; | ||||
| Assess | ||||||
| Structure of human SIRT3 in complex with SRT1720 inhibitor | monomer | 1×CNA; 1×SR7; 1×ZN; | ||||
| Assess | ||||||
| Structure of human SIRT3 in complex with ADP-ribose | monomer | 1×ZN; 1×NA; 1×AR6; 1×OP2; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF HUMAN SIRT3 IN COMPLEX WITH THE INHIBITOR EX-527 AND 2'-O-ACETYL-ADP-RIBOSE | monomer | 1×OCZ; 1×OAD; 1×ZN; 1×NA; 1×CL; | ||||
| Assess | ||||||
| Complex of human Sirt3 with Bromo-Resveratrol and Fluor-De-Lys peptide | monomer | 1×ZN; 1×BVB; 1×IPA; 3×GOL; | ||||
| Assess | ||||||
| Crystal structure of human Sirt3 in complex with Fluor-de-Lys peptide and piceatannol | monomer | 1×ZN; 1×PIT; 1×IPA; | ||||
| Assess | ||||||
| Crystal structure of human Sirt3 at an improved resolution | monomer | 1×ZN; 3×PEG; 1×MG; | ||||
| Assess | ||||||
| Crystal structure of hSIRT3 in complex with a specific agonist Amiodarone hydrochloride | monomer | 1×ZN; 1×MG; 1×BBI; 1×NAD; 1×MCM; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF SIRT3 IN COMPLEX WITH THE INHIBITOR EX-527 AND NAD | monomer | 1×NAD; 1×APR; 1×OCZ; 1×ZN; 1×NO3; 2×GOL; 1×NA; 1×CL; | ||||
| Assess | ||||||
1 SWISS-MODEL model
| Template | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 8bbk.1.A | monomer | 0.87 | 1×ZN; | 100.00 | ||
| Assess | ||||||
1 SWISS-MODEL model built on isoform sequence
| Template | Isoform | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) |
|---|---|---|---|---|---|---|
| Isoform 2 | 8ccw.1.A | monomer | 0.89 | 1×SER; 1×ZN; | 100.00 | |
| Assess | ||||||